CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Cumberland Pharmaceuticals (CPIX) Reports Q4 Loss of $0.05/sh
March 7, 2023 4:38 PM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of ($0.05). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.07 million.
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
... More